MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Halozyme Therapeutics ROCE Ratio 2011-2026 | HALO
Annual ROCE Ratio Halozyme Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 960.8 | 151.58 | 402.79 | 157.56 | 140.09 | 95.5 | -14.08 | -23.83 | 20.84 | -40.21 | -23.0 | -44.5 | -105.36 | -46.32 | -40.94 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 960.8 | -105.36 | 106.06 |
Quarterly ROCE Ratio Halozyme Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 169.48 | 162.29 | 141.95 | 130.29 | 165.72 | 165.09 | 187.13 | 179.67 | 265.55 | 316.0 | 265.07 | 126.57 | 153.4 | 94.36 | 160.45 | 179.59 | 206.27 | 206.12 | 147.98 | 44.11 | 17.37 | -36.04 | -70.84 | -38.74 | -48.97 | -32.47 | -25.3 | -27.83 | -23.95 | -9.84 | -14.0 | -21.56 | 48.46 | 114.6 | 193.71 | 186.68 | 132.64 | 8.58 | -48.46 | -76.55 | -122.56 | -114.53 | -160.5 | -143.12 | -50.61 | 87.92 | 234.71 | 295.7 | 254.7 | 121.18 | -18.23 | -100.75 | -53.47 | 34.8 | 91.96 | -12.94 | 47.27 | 28.4 | -88.62 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 316.0 | -160.5 | 68.24 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.5 | 1.86 % | $ 3.73 B |  USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 327.16 | 2.39 % | $ 42.9 B | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Amgen
AMGN
|
104.87 | $ 349.22 | 2.71 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.18 | 1.33 % | $ 447 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.57 | 5.59 % | $ 3.13 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.48 | 8.46 % | $ 394 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.85 | 2.41 % | $ 9.26 B |  Australia |
 |
BioNTech SE
BNTX
|
-4.81 | $ 91.76 | 2.39 % | $ 27.2 B | Germany |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.71 | 5.51 % | $ 17 M | USA |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-107.83 | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 3.06 | 0.99 % | $ 6.66 B | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.06 | -0.33 % | $ 307 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
-13.52 | $ 1.9 | 2.99 % | $ 362 M | USA |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.7 | 1.8 % | $ 199 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-109.6 | $ 0.36 | 0.28 % | $ 4.12 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-69.06 | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
27.01 | $ 25.57 | 2.3 % | $ 3.13 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
453.99 | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-123.17 | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-269.17 | $ 2.81 | 2.18 % | $ 7.33 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-60.12 | - | - | $ 2.18 B | USA |